CTSONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Cytosorbents Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.96+0.85 (+20.68%)
Close on Oct 19, 2026
- Market cap
- $311.52M
- P/E (TTM)
- –
- Dividend yield
- –
Cytosorbents Corp revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total product sales | – | – | – | – | – | – | – | $8.61M | $8.84M | $8.99M | $7.35M | $7.75M | – | – |
| Other product sales | – | – | – | – | – | – | – | $26.52K | $11.40K | $24.73K | $14.40K | $44.93K | – | – |
| Government grants | – | – | – | – | – | – | – | $777.59K | $1.05M | $796.77K | $1.32M | $1.06M | – | – |
| CytoSorb sales | – | – | – | – | – | – | – | $8.59M | $8.83M | $8.96M | $7.33M | $7.71M | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All other countries | $6.89M | $6.13M | – | – | $6.20M | $5.87M | – | – | – | – | – | – | 71.5% | +11.1% |
| Germany | $2.54M | $2.61M | – | – | $3.36M | $2.80M | – | – | – | – | – | – | 26.4% | -24.3% |
| United States | $200.00K | $118.00K | – | – | $61.00K | $63.00K | – | – | – | – | – | – | 2.1% | +227.9% |
From the segment and revenue-disaggregation notes of Cytosorbents's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.